Aura Biosciences, Inc.

NasdaqGM:AURA Stok Raporu

Piyasa değeri: US$839.4m

Aura Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Natalie Holles

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliğin/a
Yönetim ortalama görev süresi2.1yrs
Yönetim Kurulu ortalama görev süresi5.1yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Nov 26

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 15

Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer

Summary Aura Biosciences has continued its long work on bel-sar in cancers of the eye, bringing to bear some very interesting signals. While they have sufficient funding for now, their own timelines to a phase 3 readout suggest they will face a cash crisis well in advance of topline, pivotal data. I am upgrading AURA stock to a "hold" sentiment based on a more favorable timeline, but not a buy due to severe risks of failure of their trials. Read the full article on Seeking Alpha
Analiz Makalesi • May 03

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jan 11

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 17

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Summary Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies. Despite minor cash risks, Aura's strong data, unmet medical need focus, and solid execution make it a compelling biotech investment. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 11

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Oct 03

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analiz Makalesi • Mar 28

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Oct 01

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences (NASDAQ:AURA) is trading higher in the morning hours Tuesday after JMP Securities issued an Outperform rating as it started coverage on the clinical-stage biotech citing its novel therapeutic platform. The virus-like drug conjugates (VDC) platform Aura (AURA) is advancing “could establish a new standard of care in multiple cancer indications,” the analyst Jonathan Wolleben wrote with an DCF-derived price target of $26 per share for the stock. The firm highlights Aura’s (AURA) VDC candidate, AU-011, which is undergoing studies for choroidal melanoma, the commonest primary ocular cancer in adults, according to the analyst. In addition, JMP notes that Phase 2 data expected in the fall for AU-011 should de-risk the pivotal trial for the candidate scheduled to start later this year. In March, Aura (AURA) announced that the European Commission issued orphan drug designation for AU-011 as a treatment for several conditions of uveal melanoma, including choroidal melanoma.
Seeking Alpha • Jun 30

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' (NASDAQ:AURA) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate, which it is developing for multiple oncology indications. "This milestone supports our goal to advance the development of belzupacap sarotalocan for patients with NMIBC in need of better and earlier targeted treatment options with the potential to help preserve the bladder," said Cadmus Rich, chief medical officer and head of R&D, Aura. The company said its phase 1 trial of AU-011 in this indication is expected to begin in H2 2022, with initial data expected in 2023. AURA +3.02% to $12.95 premarket June 30
Analiz Makalesi • Apr 10

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Natalie Holles (52 yo)

less than a year
Görev süresi

Ms. Natalie C. Holles is Independent Director of LeonaBio, Inc. from May 5, 2026. Ms. Natalie C. Holles is President, CEO & Director of Aura Biosciences, Inc. from April 30, 2026. Ms. Holles served as Chie...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Anthony Gibney
Chief Financial & Business Officer1yrUS$2.82m0.052%
$ 433.3k
Jill Hopkins
Chief Medical Officer & President of Research and Development2.6yrsUS$2.19m0.054%
$ 457.0k
Natalie Holles
Presidentless than a yearVeri yokVeri yok
Amy Elazzouzi
Interim Principal Accounting Officer1.7yrsVeri yok0.11%
$ 913.7k
Mark Plavsic
Chief Technology Officer2.7yrsVeri yok0.22%
$ 1.9m
Conor Kilroy
Chief Legal Officer & Secretary2.1yrsUS$2.13m0.036%
$ 301.7k
Patrick Nealon
Senior Vice President of Clinical Development Operations3.3yrsVeri yokVeri yok
Anthony Daniels
VP & Therapeutic Area of Head Ocular Oncology3.3yrsVeri yokVeri yok
Joe McQuaid
VP & Therapeutic Area Head of Urologic Oncologyless than a yearVeri yokVeri yok
2.1yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş

Deneyimli Yönetim: AURA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Natalie Holles
Presidentless than a yearVeri yokVeri yok
Evangelos Gragoudas
Scientific & Clinical Advisorno dataVeri yokVeri yok
Sapna Srivastava
Independent Director5yrsUS$213.27k0.0095%
$ 79.9k
Jay Duker
Scientific & Clinical Advisorno dataVeri yokVeri yok
Antony Mattessich
Independent Director4.7yrsUS$214.89k0.0095%
$ 79.9k
Giovanni Mariggi
Independent Director7.1yrsVeri yokVeri yok
Richard Carvajal
Scientific & Clinical Advisorno dataVeri yokVeri yok
David Johnson
Independent Chairman of the Board5.3yrsUS$235.33k0.28%
$ 2.3m
Arun Singh
Scientific & Clinical Advisorno dataVeri yokVeri yok
Carol Shields
Scientific & Clinical Advisorno dataVeri yokVeri yok
Brian Marr
Scientific & Clinical Advisorno dataVeri yokVeri yok
Karan Takhar
Independent Director5.2yrsVeri yokVeri yok
5.1yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: AURA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/27 15:54
Gün Sonu Hisse Fiyatı2026/05/27 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Aura Biosciences, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Edward WhiteH.C. Wainwright & Co.